deltatrials

Stage iv cutaneous melanoma ajcc v6 and v7 Trials in Columbus, United States

Conditions / Stage iv cutaneous melanoma ajcc v6 and v7 / Columbus, United States

Research into Stage iv cutaneous melanoma ajcc v6 and v7 spans multiple therapeutic approaches and trial phases.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID Title Status Phase
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT02339571 A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING
NCT01274338 Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery ACTIVE_NOT_RECRUITING

Related Pages